phase 2 trial - Medxy AI

CM313, a Novel Anti-CD38 Monoclonal Antibody, Demonstrates Promising Efficacy and Safety in Persistent or Chronic Primary Immune Thrombocytopenia: Insights from a Phase 2 Randomized Trial

By MedXY 10/31/2025

The phase 2 trial shows that CM313 significantly improves platelet response rates and duration with manageable safety in adults with persistent or chronic primary immune thrombocytopenia.

Gastroenterology news Oncology

Conversion Therapy with Tislelizumab, Lenvatinib, and GEMOX in Unresectable Locally Advanced Biliary Tract Cancer: The ZSAB-TransGOLP Phase 2 Study

By MedXY 10/15/2025

The ZSAB-TransGOLP study demonstrates the promising efficacy and manageable safety of combining tislelizumab, lenvatinib, and GEMOX chemotherapy as a conversion therapy for unresectable locally advanced biliary tract cancer, achieving a 63% R0 resection rate.

Clinical Updates Hematology-Oncology news Specialties

Advancing Care in Older Adult T-Cell Leukemia/Lymphoma: Phase 2 Trial of Moga-CHOP-14 Combination Therapy

By MedXY 09/18/2025

A phase 2 study demonstrated that combining mogamulizumab with CHOP chemotherapy improves progression-free survival in older patients with adult T-cell leukemia/lymphoma, highlighting a promising first-line option.

Clinical Updates Gastroenterology news Specialties

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.